TRL-TAG2-1: A Drug Target / Disease Biomarker (G100189151)

Target Name: TRL-TAG2-1

NCBI ID: G100189151

TRL-TAG2-1

Other Name(s): Transfer RNA-Leu (TAG) 2-1 | tRNA-Leu (anticodon TAG) 2-1 | TRNAL15

TRL-TAG2-1: A Drug Target / Disease Biomarker

TRL-TAG2-1 is a drug target and a biomarker that is being studied for its potential role in treating various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. TRL-TAG2-1 is a transmembrane protein that is expressed in many different tissues and cells in the body. It is a key regulator of the T-cell receptor (TCR), which is a critical signaling system that helps the immune system recognize and respond to foreign substances in the body.

One of the main functions of TRL-TAG2-1 is to regulate the activity of T cells, which are a critical part of the immune system. T cells are responsible for recognizing and responding to threats such as viruses, bacteria, and cancer cells. When a T cell encounters a foreign substance, it is able to recognize it through the TCR, which is a protein that is expressed in the surface of the T cell. The TCR helps the T cell determine whether the foreign substance is dangerous and should be eliminated.

TRL-TAG2-1 plays a key role in regulating the activity of T cells by helping them to recognize and respond to foreign substances. It does this by interacting with a protein called CD28, which is also a key regulator of the TCR. CD28 helps to stimulate the T cell to divide and become activated, which is necessary for it to be able to recognize and respond to foreign substances.

In addition to its role in regulating T cell activity, TRL-TAG2-1 is also being studied for its potential as a drug target. This is because it is involved in many different signaling pathways that are involved in the development and progression of various diseases. For example, TRL-TAG2-1 has been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. It is also being investigated as a potential therapeutic for cancer, with studies showing that it may be able to inhibit the growth of cancer cells.

Overall, TRL-TAG2-1 is a drug target and biomarker that is being studied for its potential role in treating a variety of diseases. Its ability to regulate T cell activity and its involvement in multiple signaling pathways make it an attractive target for researchers to investigate further. Further studies are needed to fully understand the potential of TRL-TAG2-1 as a drug and to determine its effectiveness in treating various diseases.

Protein Name: TRNA-Leu (anticodon TAG) 2-1

The "TRL-TAG2-1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRL-TAG2-1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets